Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 320 followers
Latest posts
Last updated 5 days ago
Reminder: Invitation to Roche’s Virtual IR Digitalization Day
5 days ago
We are pleased to invite investors and analysts to participate in our...
Invitation: Roche’s Virtual IR Digitalization Day
16 days ago
We are pleased to invite investors and analysts to participate in our...
Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024
19 days ago
Basel, 05 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced...
Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease
24 days ago
New data highlight the potential of the Roche Elecsys® Amyloid Plasma Panel...
Reminder: Invitation to Roche’s Virtual Neurology Investor Event
27 days ago
We are pleased to invite investors and analysts to participate in our...
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months
about 1 month ago
Group sales grew by 6%1 at constant exchange rates (CER) (2% in...
Reminder: Invitation to Roche’s 3rd Quarter Sales 2024 Presentation
about 1 month ago
Roche will publish its Sales for the 3rd Quarter of 2024 prior...
Majority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate
about 1 month ago
Positive data confirm Evrysdi efficacy and safety in children first treated pre-symptomatically...
Roche submits science-based targets for net zero by 2045
about 1 month ago
Basel, 11 October 2024 - Roche announced today its submission of greenhouse...
FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
about 1 month ago
Approval is based on Phase III INAVO120 results, showing the Itovebi™ (inavolisib)-based...
Invitation: Roche’s Virtual Neurology Investor Event
about 2 months ago
We are pleased to invite investors and analysts to participate in our...
Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis
about 2 months ago
Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy...